Expansion Adds to Growing Global Trial FootprintPatient Screening and Enrollment Expected to Begin in Q2 2026SOUTH SAN FRANCISCO, Calif., April ...

A new study published in The Journal of Immunology by researchers at the Josep Carreras Leukaemia Research Institute (IJC) ...

By enrolling the world's first participant, the Sarah Cannon Transplant & Cellular Therapy Program at St. David's South Austin Medical Center made this therapy available to patients before it was ...

To Highlight Efficacy Results from Relapsed or Refractory Waldenström Macroglobulinemia Patients Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy FLORHAM PARK, N.J., April 21, ...

Researchers at the Josep Carreras Leukaemia Research Institute (IJC) discover that a single molecular switch, HDAC7, controls ...

Deep in the lungs, resident memory B cells stand guard against influenza reinfection—but whether they remain there may depend ...

Verismo Therapeutics, a clinical-stage CAR T cell therapy company pioneering a novel multi-chain KIR-CAR platform technology, ...

By using CRISPR/Cas9 to engineer cells from healthy donors, AVC-203 is designed to circumvent graft-versus-host disease and host-mediated rejection.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities ...

Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that the U.S. Food and Drug Administration ...

For decades, the standard explanation for autoimmune diseases like rheumatoid arthritis has rested on two pillars: inherited ...

First patient dosing occurred for JANX011 (NCT07291323), a CD19-targeted bispecific inaugurating the ARM platform to enable ...